
UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients
UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing and commercializing innovative treatments for urothelial…












